Table 2.
Risperidone | Olanzapine | Quetiapine | Ziprasidone | Aripiprazole | FGAs | No medication | |
---|---|---|---|---|---|---|---|
Subjects (M/F) |
47 (35/12) |
13 (6/7) |
44 (29/15) |
2 (2/0) |
1 (0/1) |
5 (3/2) |
39 (22/17) |
Mean Age (SD) |
11.54 (3.13) |
15.16 (2.12) |
13.31 (2.97) |
14.63 (0.36) |
16.77 |
15.22 (1.16) |
11.88 (3.27) |
Mean Dose mg (SD) |
1.18 (0.78) |
10.77 (4.83) |
196.02 (175.58) |
30.00 (14.14) |
7.50 |
- |
- |
CPZ Equiv mg (SD) |
58.78 (39.09) |
215.38 (96.58) |
261.36 (234.10) |
50.00 (23.57) |
100.00 |
119.29 (111.33) |
- |
On-Label Use (% of total on drug) |
11 (23.4) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (100.0) |
0 (0.0) |
- |
Off-Label Use (% of total on drug) |
36 (76.6) |
13 (100.0) |
44 (100.0) |
2 (100.0) |
0 (0.0) |
5 (100.0) |
- |
Titrated Switch Pre Hosp (% of switches) |
1 (3.1) |
2 (6.3) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (3.1) |
2 (6.3) |
Titrated Switch Post Hosp (% of switches) |
1 (3.1) |
2 (6.3) |
2 (6.3) |
0 (0.0) |
1 (3.1) |
0 (0.0) |
0 (0.0) |
Immediate Switch Pre Hosp (% of switches) |
0 (0.0) |
0 (0.0) |
2 (6.3) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
2 (6.3) |
Immediate Switch Post Hosp (% of switches) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
Gap Switch Pre Hosp (% of switches) |
0 (0.0) |
2 (6.3) |
3 (9.4) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
3 (9.4) |
Gap Switch Post Hosp (% of switches) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
Overlapped Switch Pre Hosp (% of switches) |
3 (9.4) |
1 (3.1) |
4 (12.5) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
2 (6.3) |
Overlapped Switch Post Hosp (% of switches) | 0 (0.0) | 0 (0.0) | 1 (3.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
139 patients were identified who had been treated with an antipsychotic drug either during hospital admission or in the 52 weeks prior to admission. Table indicates characteristics of groups based on different antipsychotic drug treatments at time of discharge. FGA = First Generation Antipsychotic; CPZ = Chlorpromazine.